[go: up one dir, main page]

CL2013001854A1 - Anti-pcsk9 antibody or a fragment thereof comprising a variable domain; nucleic acid; vector; host cell; method of obtaining; pharmaceutical composition; and its use to treat hypercholesterolemia in a subject. - Google Patents

Anti-pcsk9 antibody or a fragment thereof comprising a variable domain; nucleic acid; vector; host cell; method of obtaining; pharmaceutical composition; and its use to treat hypercholesterolemia in a subject.

Info

Publication number
CL2013001854A1
CL2013001854A1 CL2013001854A CL2013001854A CL2013001854A1 CL 2013001854 A1 CL2013001854 A1 CL 2013001854A1 CL 2013001854 A CL2013001854 A CL 2013001854A CL 2013001854 A CL2013001854 A CL 2013001854A CL 2013001854 A1 CL2013001854 A1 CL 2013001854A1
Authority
CL
Chile
Prior art keywords
fragment
vector
obtaining
subject
nucleic acid
Prior art date
Application number
CL2013001854A
Other languages
Spanish (es)
Inventor
Yan Wu
Cecilia Chiu
Daniel Kirchhofer
Andrew Peterson
Ganesh Koluman
Beltran Monica Kong
Paul Moran
Wei Li
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2013001854A1 publication Critical patent/CL2013001854A1/en

Links

CL2013001854A 2010-12-22 2013-06-21 Anti-pcsk9 antibody or a fragment thereof comprising a variable domain; nucleic acid; vector; host cell; method of obtaining; pharmaceutical composition; and its use to treat hypercholesterolemia in a subject. CL2013001854A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201013614263A 2010-12-22 2010-12-22
US201113614777A 2011-04-21 2011-04-21

Publications (1)

Publication Number Publication Date
CL2013001854A1 true CL2013001854A1 (en) 2014-03-07

Family

ID=52014895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001854A CL2013001854A1 (en) 2010-12-22 2013-06-21 Anti-pcsk9 antibody or a fragment thereof comprising a variable domain; nucleic acid; vector; host cell; method of obtaining; pharmaceutical composition; and its use to treat hypercholesterolemia in a subject.

Country Status (1)

Country Link
CL (1) CL2013001854A1 (en)

Similar Documents

Publication Publication Date Title
CL2013000545A1 (en) Anti-ox40 antibody; nucleic acid encoding it; host cell; Method of production; and its use to treat cancer or an autoimmune disease.
CO6900138A2 (en) New sulfoxides of piperidino-dihydrotienopyrimidine and its use to treat epoc and asthma
CL2013003336A1 (en) Human anti-cgrp antibody; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical and diagnostic composition that includes it; and its therapeutic use
CL2013001975A1 (en) Individual variable domain of anti-tgfbetarii immunoglobulin; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition; and its use to treat a disease associated with tgfbeta signaling.
BR112014018136A2 (en) antibodies or use and method to determine
CL2014000958A1 (en) Antibody polypeptides that antagonize cd4ol; nucleic acid encoding said antibody; vector and host cell that comprise it; pharmaceutical composition; use of said polypeptides to treat immune disease.
CL2013003043A1 (en) Antibodies from a single dab variable domain that bind to human cd40; nucleic acid encoding said antibody; vector and host cell that comprise it; pharmaceutical composition; use of said antibodies to treat immune disease.
BR112013013781A2 (en) humanized antibodies to liv-1 and use them to treat cancer
CL2013001776A1 (en) Isolated antibody that binds to mesothelin; nucleic acid encoding it; host cell; Method of production; immunoconjugate; pharmaceutical formulation that includes it; its use to treat cancer; and method of detection of human mesothelin.
AR091098A1 (en) ANTIBODIES AND IMMUNOCATED TO Ly6E AND METHODS OF USE
HRP20160854T1 (en) OLIGONUCLEOTIDS FOR MAKING CHANGES IN THE SEQUENCE OF THE TARGET MOLECULES MOLECULES PRESENT IN THE LIVING CELL
PL2552959T3 (en) Antibodies against MUC16 and methods of use
CL2014000183A1 (en) Pharmaceutical formulation containing anti-pcsk9 antibodies; method to prepare said formulation.
CL2013001625A1 (en) Binding protein that specifically binds to tnf-alpha; nucleic acid encoding it; vector; host cell; Method of production; pharmaceutical composition that includes it; and its use to treat a disease or disorder associated with tnf-alpha.
CL2015000092A1 (en) Chirally controlled oligonucleotides, composition comprising them; Method of elaboration: and use to treat cancer.
AR089752A1 (en) ANTI-LRP5 ANTIBODIES AND METHODS OF USE
PT3214091T (en) USE OF CHEMICAL ANTIGEN RECEIVER-MODIFIED T CELLS TO TREAT CANCER
IL233742B (en) Antibodies to integrin αvβ6 and use of same to treat cancer
BR112014009837A2 (en) Effective use of yeast and yeast extract
CL2007001488A1 (en) Human or humanized anti-integrin alpha5beta1 antibody; nucleic acid encoding it; vector and host cell that comprise it; production procedure; pharmaceutical composition that includes it; and its use to prevent or treat disorders associated with integrin.
BR112014012590A2 (en) anti-cd98 antibodies and methods of use
PL3489261T3 (en) Antibodies and vaccines for use in the treatment of ROR1 expressing tumors and in the inhibition of metastasis
CL2011002611A1 (en) Isolated anti-cadherin-17 antibody; nucleic acid molecule that encodes it; vector; host cell; Method of production; immunoconjugate that understands it; composition that includes it; and its use to treat or prevent a disease associated with target cells expressing cadherin-17.
BR112014015472A2 (en) computer method and program for monitoring the use of an absorbent product
CL2013002811A1 (en) Isolated monoclonal antibody that binds to an epitope of the human tissue factor pathway inhibitor; nucleic acid molecule that encodes it; pharmaceutical composition that includes it; and its use to treat deficiencies or genetic or acquired defects in coagulation.